Early ovarian cancer surgical staging important clinical value

A scholar from the Netherlands led multinational collaborative research suggest that the early epithelial ovarian cancer surgical staging, can predict whether the patients have residual ovarian cancer and the need for postoperative adjuvant chemotherapy.

Tags: age, cancer, carcinoma, cases, cell, chemotherapy, cisplatin, clinical, early, examination, group, ovarian, patients, poor, prognosis, rate, residual, staging, surgery, surgical, survival, therapy, time, tumor

Two new studies provided information on the latest news of ovarian cancer

【Medical industry network HealthDayNews2003 According to the July 3 - now on the younger female epithelial ovarian cancer, some important information: your chances of survival much more than older patients.

In July, "Obstetrics and Gynecology" (Obstetrics andGynecology), the journal published a new study, the researchers found: diagnosis of advanced epithelial ovarian cancer in women aged under 45 of the 5-year survival than those over the age of 45 is two times bigger. "If all other aspects of the same, young patients can live better," the author, Stamford University professor Chen (JohnChan): In fact, even if it is possible to study the impact of factors, such as other health problems, age patients still live better.

Tags: age, blood, cancer, clinical, diagnosis, early, gene, group, groups, growth, method, ovarian, patients, positive, rate, response, study, surgery, survival, time, tumor, women

Ovarian cysts clinical classification

Serous cystadenoma
Zhu serous tumor of the kidney from the body cavity epithelium, is the most common tumors of the ovary. According to national statistics, the total of 2007-09-07 16:00:00.1% of ovarian tumors common in women aged 30-40. The unilateral nature, but there are also many of the bilateral. Simple solution can be divided into gland capsule and two papillary serous cystadenoma.

Tags: abdominal, age, amenorrhea, annex, anti, benign, bleeding, blood, body, breast, cancer, carcinoma, cases, cause, cell, cells, children, clinical, cyst, cystic, cysts, diagnosis, early, eat, ert, estrogen, gene, group, groups, growth, incidence, increased, malignant, mass, metastasis, metastatic, oppression, ovarian, ovary, patients, pelvic, poor, prognosis, protein, quality, radiation, rate, resection, surface, surgery, surgical, survival, symptoms, time, treatment, tumor, tumors, usually, uterine, women

Daqing City in Heilongjiang hospital recently adopted a new therapy combining traditional Chinese and western medicine, ultrasound-guided puncture, self-developed "Gallnut hardening agent" for the treatment of ovarian cysts, to date a total of more than 400 patients is associated disarmed.

"Gallnut hardening agent" by gallnut, brucea javanica, Yuan Hu, the group formed by the injection of a scientific process. Modern pharmacology studies confirmed: Gallnut obvious convergence, enable protein containing tannic acid precipitation; Brucea javanica contained Brucea javanica oil, could undermine something superfluous cell nucleus; Yuan Hu good analgesic effect.

Tags: age, cell, cells, cyst, cysts, drug, eat, group, injection, ovarian, patients, protein, therapy, treatment

Recurrent ovarian cancer chemotherapy new method - conventional chemotherapy drug efficacy forecast molecular targeted chemotherapy

Ovarian cancer is the worst prognosis of gynecologic tumors. Patients with advanced epithelial ovarian cancer five-year survival rates generally below 30%, mainly in patients with relapsing most (about 75%), relapse after chemotherapy to poor results.

For the treatment of recurrent ovarian cancer chemotherapy drugs many, no less than 10 species, but only clinical remission rate of 20% to 30%, no progress median survival time (PFS) for 2 to 6 months, the median overall survival (OS) for six to 12 months. Therefore, to improve the efficacy of chemotherapy drugs delay, but the development of new drugs is very difficult, efficient use of existing drugs is an effective way to <BR>.

Tags: cancer, cases, chemotherapy, cisplatin, clinical, drug, drugs, early, eat, exploration, gene, group, method, ovarian, p53, paclitaxel, patients, pmtc, poor, positive, prognosis, rate, second, study, survival, taxol, therapy, time, treatment, tumor, tumors

Treatment of ovarian cancer chemotherapy new program

Researchers reported that the joint use of both cisplatin and paclitaxel chemotherapy drug for ovarian cancer achieved better clinical remission rate and a higher survival rate, this new program has become advanced ovarian cancer patients with standard treatment programs.

From the European Organization for Cancer Research and Treatment of Dr Piccart, a group of researchers across the Atlantic to the two large-scale clinical trials group that cisplatin and paclitaxel (TP) both chemotherapy treatment of advanced ovarian cancer with significant advantages.

Tags: age, anti, cancer, chemotherapy, cisplatin, clinical, drug, eat, grams, group, history, ovarian, paclitaxel, patients, rate, study, survival, therapy, treatment, tumor, tumors

Intraperitoneal chemotherapy should be first-line therapy in ovarian cancer

A large number of pre-clinical data and the right abdominal anatomy, physiology and biology of ovarian cancer have suggested that understanding, abdominal local cytotoxic drug treatment for ovarian cancer is very reasonable. Intraperitoneal chemotherapy Phase I clinical trial confirmed the chemotherapy drugs and intraperitoneal chemotherapy safety of the technology itself, confirmed the intraperitoneal chemotherapy in the pharmacokinetic advantages.

In some multi-center Phase II clinical trials, surgical results confirmed that about 20% to 40% of second-tier category to cisplatin-based chemotherapy in patients with celiac complete remission, the part of the residual cancer patients <0.5 cm before  acceptable to platinum-based chemotherapy effective systemic System .

Tags: abdominal, administration, age, cancer, carboplatin, cause, chemotherapy, cisplatin, clinical, days, drug, drugs, eat, group, incidence, infusion, injection, intraperitoneal, intravenous, ovarian, paclitaxel, pain, patients, rate, reduce, residual, second, study, surgical, survival, taxol, therapy, time, toxicity, treatment, tumor

Basic knowledge of ovarian cancer pathology

Disease Overview

Tags: age, breast, cancer, carcinoma, cause, cell, cells, chemotherapy, children, diagnosis, early, eat, ert, fat, gene, group, incidence, increased, knowledge, life, lymph, malignant, metastatic, ovarian, patients, preventive, radiotherapy, rate, risk, second, surface, surgery, survival, symptoms, tea, therapy, time, treatment, tumor, tumors, uterine, women

Summary of ovarian cancer

Epithelial ovarian cancer in the United States is a relatively rare in Gynecologic Oncology, 2004, there were approximately 25,580 cases of new onset patients, 16,090 cases patients died. The majority of patients with advanced cancer, treatment for surgical resection and postoperative to platinum-based chemotherapy. During the past 10 years, chemotherapy improved survival rates improve, and recurrent tumor treatment more effective. In addition, the genetic risk factors for making in-depth understanding of the prevention strategy to become individualized approach to bilateral tubal women - ovarian surgery. This report summarized the clinical characteristics of epithelial ovarian, after reports focus on the treatment of the latest developments.

Tags: age, brca1, breast, cancer, carcinoma, cases, cause, chemotherapy, clinical, diagnosis, drug, drugs, early, eat, ert, estrogen, examination, family, gene, group, groups, history, incidence, increased, life, malignant, mutation, ovarian, ovary, patients, pelvic, preventive, protein, rate, reduce, resection, risk, screening, second, study, surface, surgery, surgical, survival, syndrome, therapy, time, treatment, tumor, usually, women

Ovarian cancer care

One, paclitaxel and cisplatin in the treatment of advanced ovarian cancer care <BR> <BR> 1990s Taxol is more of the treatment of advanced ovarian cancer drug effective, and its unique mechanism is a new type of anti-tubulin role of antitumor drugs. Cisplatin for inorganic platinum metal complex, the cell cycle-specific drug, can inhibit DNA synthesis, combined with their synergies to enhance the effectiveness of [1]. In Division I from July 1996 to July 1998 to 15 cases of advanced ovarian cancer patients with Taxol and cisplatin in the treatment of satisfactory results.

One, information and Methods

Tags: administration, age, anti, blood, body, cancer, care, cases, cause, cell, cells, chemotherapy, cisplatin, clinical, confidence, days, diet, dose, drug, drugs, eat, ert, estrogen, family, fat, gene, group, growth, incidence, infusion, injection, intravenous, life, mass, metastasis, method, ovarian, paclitaxel, pain, patients, physical, poor, positive, psychological, quality, rate, reduce, response, skin, surface, surgery, survival, symptoms, taxol, therapy, time, toxicity, treatment, tumor, tumors, women